News
FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and ...
A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback